Heron Therapeutics, Inc.
NASDAQ:HRTX · NASDAQ Capital Market
+$0.01 today
Vol 5.46M · Avg 2.90M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-140.9%
avg -92.2%
ROIC
-1.6%
avg -109.4%
ROA
-7.9%
avg -69.3%
Analysis
ROIC is currently the strongest return metric at -1.6% versus its period average of -109.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Craig Alexander Collard | Chief Executive Officer & Director | $1.22M | — | 60 | $757,885.00 | 0.48% |
William Forbes D. | Executive Vice President & Chief Development Officer | $914,890.00 | — | 64 | $221,611.00 | 0.14% |
Ira Duarte | Executive Vice President & Chief Financial Officer | $857,803.00 | — | 57 | $264,628.00 | 0.17% |
Mark E. Hensley | Executive Vice President & Chief Operating Officer | $748,854.00 | — | 43 | $375,000.00 | 0.24% |
Jeff Cohn | Executive Director, Assistant General Counsel & Assistant Secretary | — | — | 44 | — | — |
Ryan Craig | Vice President of Marketing | — | — | — | $757,885.00 | 0.48% |
John C. Arthur | Senior Vice President of Manufacturing Development | — | — | 60 | $48,660.00 | 0.03% |
Melissa Jarel | Vice President of Legal | — | — | — | — | — |
Robert Sullivan | Chief Commercial Officer | — | — | 48 | $100,000.00 | 0.06% |
Brett Fleshman | Chief Business Officer | — | — | — | — | — |
John Aiken | Executive Director of People Management & Training | — | — | — | $48,660.00 | 0.03% |
Kevin Warner | Senior Vice President of Medical Affairs Strategy & Engagement | — | — | — | $540,000.00 | 0.34% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$6.34M
Sells
0
$0.00
Net Sentiment
+$6.34M
Net buying
Most Active
Rubric Capital Management LP
3 transactions
Analysis
Insiders reported 5 buys worth $6.34M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $6.34M. Rubric Capital Management LP was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
$1.19B
Genfit S.A.
GNFT
$445.68M
OmniAb, Inc.
NASDAQ:OABI
$267.42M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$212.10M
Coherus Oncology, Inc.
NASDAQ:CHRS
$174.43M
Protalix BioTherapeutics, Inc.
AMEX:PLX
$170.41M
Protara Therapeutics, Inc.
NASDAQ:TARA
$155.32M
MediWound Ltd.
NASDAQ:MDWD
$153.38M
Invivyd, Inc.
NASDAQ:IVVD
$124.75M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$99.78M
Who manages HRTX?
Heron Therapeutics, Inc. (HRTX) lists 12 active executives. The top listed executive is Craig Alexander Collard, Chief Executive Officer & Director.
Are HRTX insiders buying or selling?
Recent insider activity shows net buying of $16.46M.
Explore More
Continue the stock analysis
Jump to another research area for this company.